Stock Events

Stock Events

Kala Bio 

0
75
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q1 2026
Q2 2026
Next
-7.31
-6.59
-5.86
-5.14
Expected EPS
-5.3309999999999995
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-23.59MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 27F.STU. It's not an investment recommendation.
Tesla
10
TSLA
Apple
9
AAPL
Amazon
9
AMZN
NVIDIA
9
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.13B
Regeneron Pharmaceuticals competes in the ophthalmology space with treatments for eye diseases, directly competing with Kala's eye care products.
Novartis
NVS
Mkt Cap276.48B
Novartis offers a range of eye care medications, including treatments for conditions that Kala Bio targets, making them a direct competitor.
Abbvie
ABBV
Mkt Cap467.12B
AbbVie, through its acquisition of Allergan, has a strong presence in the ophthalmology market, competing with Kala Bio's eye care solutions.
Bausch Health Companies
BHC
Mkt Cap2.13B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant portfolio in eye health, competing in the same market as Kala Bio.
Biogen
BIIB
Mkt Cap33.63B
Biogen has a focus on specialty care and biologics that could compete with Kala Bio's treatments in certain niche markets.
Regenxbio
RGNX
Mkt Cap488.5M
REGENXBIO is a biotechnology company focused on the development of gene therapies for eye diseases, directly competing with Kala Bio's approach to eye care.
Gilead Sciences
GILD
Mkt Cap187.15B
Gilead Sciences, while primarily known for its work in antiviral drugs, has ventured into other therapeutic areas that could potentially compete with Kala Bio's niche markets.

About

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Show More
CEO
Avi Minkowitz
Employees
6
Country
United States
ISIN
US4831193010
WKN
000A4243T

Listings

XNAS
US
KALA
LSE
GB
0JQ2.LSE
BOATS
BOATS
KALA.BOATS
STU
DE
27F.STU

0 Comments

Share your thoughts

FAQs

What is Kala Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Kala Bio stocks are traded under the ticker 27F.STU.
When is the next Kala Bio earnings date?▼
Kala Bio is going to release the next earnings report on November 10, 2026.
What is Kala Bio revenue for the last year?▼
Kala Bio revenue for the last year amounts to 0 EUR.
What is Kala Bio net income for the last year?▼
27F.STU net income for the last year is -23.59M EUR.
How many employees does Kala Bio have?▼
As of October 5, 2026, the company has 6 employees.
In which sector is Kala Bio located?▼
Kala Bio operates in the Health & Wellness sector.
When did Kala Bio complete a stock split?▼
The last stock split for Kala Bio was on May 11, 2026 with a ratio of 1:50.
Where is Kala Bio headquartered?▼
Kala Bio is headquartered in ARLINGTON, United States.